Transcutaneous Spinal Cord Stimulation With Bladder and Pelvic Floor Muscle Training

June 10, 2024 updated by: RNOH RIC

Promoting Restoration of Function of Co-ordinated Bladder Storage and Voiding Following Spinal Cord Injury by Combination of Transcutaneous Spinal Cord Stimulation and Bladder & Pelvic Floor Muscle Training Training

Spinal Cord Injury (SCI) disrupts signals between the brain and the rest of the body, this includes signals needed to control the bladder and bowels. Spinal cord stimulation (SCS) (electrical stimulation through electrodes placed on the skin over the spine) has shown potential to improve bladder function. Additionally pelvic floor muscle training (PFMT), has been shown to help control bladder overactivity and reduce incontinence in people with a SCI.

This study will investigate PFMT with SCS, and its effects on restoring bladder function, and continence. We aim to recruit 25 participants. Those eligible will be patients from the London Spinal Cord Injury Centre with a supra-sacral SCI (>6 months post-injury), aged 16 years old and above.

Study Overview

Status

Completed

Detailed Description

The first five participants who volunteer will be invited to complete 'SCS optimisation'. Testing different SCS electrode positions and stimulation parameters with pelvic floor exercises and during urodynamics (measurement of pressure changes during filling and emptying of the bladder).

For the main study, all participants will complete baseline assessments (week 1) which include: bladder, bowel, sexual function, and quality of life questionnaires, a pelvic floor assessment, and urodynamics. Assessments will be repeated at week 8, and week 14.

After baseline assessments, participants will be randomly allocated to one of two groups. The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call. The control group will continue with usual care for 8-weeks.

At the end of the 8-weeks, all participants will be re-assessed, and will then complete a single session of SCS with urodynamics. Participants will return for their final assessment 6-weeks later (week 14). Participants allocated to the control group will be offered PFMT at the end of the study.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stanmore, United Kingdom, HA7 4LP
        • Royal National Orthopaedic Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Supra-sacral spinal cord injury over 6 months ago
  • Previous urodynamics and management by the Neuro-urology Consultants
  • Proven NDO from latest urodynamics

Exclusion Criteria:

  • Participants under 16 years of age
  • Non-stable SCI or metastatic cord disease
  • Intra-detrusor botulinum toxin injections in previous 6 months
  • Bladder infection on day of investigation
  • Pregnant or trying for a baby (females)
  • Cardiac pacemaker, bladder stimulator or baclofen pump in situ
  • Metal work at thoraco-lumbar level of stimulation
  • Poorly controlled Autonomic Dysreflexia
  • Currently involved in a clinical trial
  • Previous surgical intervention on bladder/sphincters
  • Active sepsis
  • Poorly controlled epilepsy. Acceptable where epilepsy is controlled by drugs or there have been no fits experienced for a reasonable period
  • Patients with a cancerous tumour in the area of the electrical stimulation
  • Patients without the capacity to consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bladder and Pelvic Floor Muscle Training
Participants randomised to the intervention group will complete an 8-week bladder and PFMT programme, both at the LSCIC and at home. They will be invited to 3 face-to-face follow up appointments over the 8-weeks, where they will meet with a physiotherapist to check their technique and monitor their progress. At home participants will receive a daily text reminder to complete their PFM training, they will also receive a weekly phone call from a member of the research team who will check how they are managing and whether they have any questions. At the end of the programme, participants will be asked to repeat the questionnaires and have their pelvic floor re-assessed. Following this, they will complete the urodynamic investigation with tSCS.
The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
No Intervention: Control
Participants randomised to the control group will continue with their usual care for 8-weeks. They will return to repeat their baseline questionnaires and have their pelvic floor re-assessed. Finally, they will complete tSCS bladder filling and emptying cycles with urodynamics.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in maximum cystometric capacity (MCC) from baseline to follow up
Time Frame: Week 1, 8 and 14
Bladder capacity from Cystometrogram/Urodynamic procedures (ml)
Week 1, 8 and 14
Change in maximum detrusor pressure during voiding (MDPvoid) from baseline to follow up
Time Frame: Week 1, 8 and 14
Voiding detrusor pressure measured from Cystometrogram/Urodynamic procedures (cmH20)
Week 1, 8 and 14
Change in bladder voiding efficiency from baseline to follow up
Time Frame: Week 1, 8 and 14
Bladder voiding efficiency measured from Cystometrogram/Urodynamic procedures, [[volume voided/volume voided+post void residual)*100] (%)
Week 1, 8 and 14

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pelvic Floor Oxford Grading Score
Time Frame: Week 1, 8 and 14
Measure of pelvic floor muscle strength, graded 0-5
Week 1, 8 and 14
The Neurogenic Bladder Symptom Score (NBSS)
Time Frame: Week 1, 8 and 14
Validated 24-item questionnaire, three domains: incontinence, storage and voiding, consequences (score 0-28)
Week 1, 8 and 14
Neurogenic Bowel Dysfunction Score (NBDS)
Time Frame: Week 1, 8 and 14
Bowel dysfunction questionnaire, includes questions on bowel symptoms, medication, and incontinence (score 0-47)
Week 1, 8 and 14
Arizona Sexual Experiences Scale (ASEX)
Time Frame: Week 1, 8 and 14
Five-item rating scale measuring sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm (Score 3-30)
Week 1, 8 and 14
Quality of Life Questionnaire EQ-5D-5L
Time Frame: Week 1, 8 and 14
Five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scoring 1-5 on each dimension, and a VAS scale of overall health 0-100.
Week 1, 8 and 14
The Qualiveen Questionnaire
Time Frame: Week 1, 8 and 14
30-item questionnaire, with health-related quality of life questions specific to individuals with neurogenic urinary dysfunction. Total score is mean of eight scores: bother with limitations, fears, feelings, and frequency of limitations.
Week 1, 8 and 14
Electromyography (EMG) of resting tone and maximum voluntary pelvic floor contraction
Time Frame: Week 1, 8 and 14
Use of vaginal/anal probe to capture resting tone and maximum voluntary pelvic floor contraction (mV)
Week 1, 8 and 14

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Frank Lee, Royal National Orthopaedic Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 16, 2022

Primary Completion (Actual)

September 4, 2023

Study Completion (Actual)

September 4, 2023

Study Registration Dates

First Submitted

August 15, 2022

First Submitted That Met QC Criteria

August 15, 2022

First Posted (Actual)

August 17, 2022

Study Record Updates

Last Update Posted (Actual)

June 12, 2024

Last Update Submitted That Met QC Criteria

June 10, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Cord Injuries

Clinical Trials on Bladder and Pelvic Floor Muscle Training

Subscribe